



## **Supporting Information**

### **Supplementary material**

**This appendix was part of the submitted manuscript and has been peer reviewed.  
It is posted as supplied by the authors.**

Appendix to: Khan NN, Basrai H, Evans SM, et al. Landscape of clinical trials across the pancreatic cancer care continuum: an Australian perspective. *Med J Aust* 2022; doi: 10.5694/mja2.51756.

Table 1: Key characteristics of pancreatic cancer clinical trials

Trial number	Trial ID	Trial title	Year of commencement	Intervention/exposure aligned to OCP* step	Primary sponsor
<b><i>Investigator-initiated clinical trials, focused exclusively in pancreatic cancer</i></b>					
1.	ACTRN12620001081909	The feasibility and efficacy of a multi-component exercise program in pancreatic cancer patients receiving preoperative chemotherapy	1/11/2020	Prehabilitation	Edith Cowan University
2.	ACTRN12619001033134	Bio-distribution evaluations of MUC-1 specific targeted immune-radiotherapy for advanced pancreatic adenocarcinoma: a first pilot human study.	1/08/2019	Immunotherapy	Royal Adelaide Hospital
3.	ACTRN12617001571369	Stereotactic ablative body radiotherapy for Unresectable Pancreatic cancer with Endoscopic ultrasound inserted fiducial markers and concuRrent chemotherapy (SUPER) trial.	1/12/2017	Chemotherapy and/or radiotherapy	Royal Adelaide Hospital
4.	ACTRN12617000595314	A study to evaluate the sensitivity and specificity of imaging the CXCR4 Chemokine receptor with a novel PET tracer in pancreatic cancer	1/05/2017	Specialist diagnostic work-up	Royal Brisbane and Women's Hospital
5.	ACTRN12615000647538	Evaluating the efficacy of Selective Internal Radiation (SIR) spheres in combination with chemotherapy for patients with pancreatic cancer with liver metastases	20/07/2015	Treatment (for recurrent, residual or metastatic disease)	Ringwood Private Hospital
6.	NCT03505229	Span-C-SBRT for Pancreatic Cancer	18/12/2018	Chemotherapy and/or radiotherapy	Royal North Shore Hospital
7.	ACTRN12618000335291	Circulating Tumour DNA Analysis Informing Adjuvant Chemotherapy in Early Stage Pancreatic Cancer: A Multicentre Randomised Study (DYNAMIC- Pancreas)	20/03/2019	Targeted therapy	The Australasian Gastro-Intestinal Trials Group (AGITG)
8.	ACTRN12617001642370	A study looking at the use of Mfolfirinnox Chemotherapy and Stereotactic Radiotherapy for Patients with Locally Advanced pancreatic cancer to evaluate if this is a feasible	5/04/2018	Chemotherapy and/or radiotherapy	Liverpool Hospital

		treatment option with acceptable acute toxicity rates.			
9.	ACTRN12617001242314	Endoscopic Ultrasound Guided portal vein sampling as an ultimate staging procedure in patients with pancreatic cancer: a feasibility study.	4/09/2017	Staging	The Royal Adelaide Hospital
10.	ACTRN12614001287628	Improving preoperative staging in patients with locally resectable pancreatic cancer – a randomised controlled trial comparing 12-month recurrence rate of patients managed with standard preoperative assessment of liver metastases, contrast enhanced CT (computed tomography) to preoperative assessment of liver metastases with Primovist (liver specific contrast) MRI (magnetic resonance imaging)	1/03/2019	Staging	Individual
11.	ACTRN12612000777897	The IMPACT trial: Individualised Molecular Pancreatic Cancer Therapy; a phase II trial assessing feasibility of personalised treatment based on specified tumour molecular signatures (phenotypes) of the tumour in patients with recurrent or metastatic pancreatic cancer.	14/11/2013	Treatment (for recurrent, residual or metastatic disease)	The Australasian Gastro-Intestinal Trials Group (AGITG)
12.	ACTRN12611000848909	GAP: Phase II gemcitabine and nab-paclitaxel for resectable pancreas cancer	19/06/2013	Chemotherapy and/or radiotherapy	The Australasian Gastro-Intestinal Trials Group (AGITG)
13.	ACTRN12610001047088	A randomised phase II study evaluating potential predictive biomarkers in the treatment of locally advanced and metastatic pancreatic cancer	17/04/2012	Treatment planning	The Australasian Gastro-Intestinal Trials Group (AGITG)
14.	ACTRN12619000409178	A Randomised Phase II Study of MFOLFIRINOX And Stereotactic Radiotherapy (SBRT) for Pancreatic Cancer with High Risk and Locally Advanced Disease (MASTERPLAN)	30/08/2019	Chemotherapy and/or radiotherapy	The Australasian Gastro-Intestinal Trials Group (AGITG)

15.	ACTRN12617000540314	Panitumumab as second line therapy for advanced pancreatic ductal adenocarcinoma with wild-type KRAS gene	20/03/2018	Treatment (for recurrent, residual or metastatic disease)	Individual
16.	ACTRN12614000452695	Intra-Arterial Isolation Chemotherapy for Locally Advanced Unresectable Pancreatic Cancer	30/06/2018	Chemotherapy and/or radiotherapy	Individual
17.	ACTRN12613001013752	Phase I open label trial of Abraxane (nab-paclitaxel) administered concurrently with radiotherapy in patients with locally advanced inoperable pancreatic adenocarcinoma.	10/09/2012	Chemotherapy and/or radiotherapy	Southern Adelaide Local Health Network
18.	ACTRN12612000299808	Treatment of Pancreatic Insufficiency Using Creon in Patients with Pancreatic Cancer	30/05/2012	Supportive care	Calvary Mater Newcastle
19.	ACTRN12611001172998	Pancreatic Enzyme Replacement Therapy in Pancreatic Cancer - A Randomized Controlled Trial	1/12/2011	Supportive care	Individual
20.	ACTRN12616000538448	Goal-directed Therapy for Patients Undergoing Pancreaticoduodenectomy	9/09/2013	Surgery	Austin Hospital
21.	ACTRN12617001649303	Methods of tissue preparation after Endoscopic Ultrasound guided fine-needle aspiration without rapid on-site assessment: results of a randomized study.	22/02/2017	Specialist diagnostic work-up	Royal Adelaide Hospital
22.	NCT03322592	EUS-FNB With ROSE Vs. EUS-FNB Without ROSE (FROSENR)	29/03/2018	Specialist diagnostic work-up	Azienda Ospedaliera Universitaria Integrata Verona
23.	NCT00735917	Saracatinib in Treating Patients with Previously Treated Metastatic Pancreatic Cancer	1/10/2008	Treatment (for recurrent, residual or metastatic disease)	National Cancer Institute (NCI)
24.	ACTRN12617001231336	A Head to Head Comparative Pilot Trial of Endoscopic ultrasound-guided (EUS) Core Biopsy Needles in solid pancreatic lesions: ProCore vs Shark Core and Acquire	3/09/2018	Specialist diagnostic work-up	Royal Adelaide Hospital
25.	ACTRN12609000158268 NCT00634725	Randomized multicenter phase III study in patients with locally advanced adenocarcinoma of the pancreas: gemcitabine with or without	1/02/2008	Chemotherapy and/or radiotherapy	GERCOR - Multidisciplinary Oncology Cooperative Group

		chemoradiotherapy and with or without erlotinib			
<b>Investigator-initiated cancer (including pancreatic cancer) clinical trials</b>					
26.	ACTRN12619001126101	PROpatient: Can symptom monitoring and care coordination improve the quality of life of people with upper gastrointestinal cancer.	1/06/2020	Supportive care	Monash University
27.	ACTRN12618000811202	Targeted thromboprophylaxis in ambulatory patients receiving anticancer therapies (TARGET-TP)	28/06/2018	Supportive care	Peter MacCallum Cancer Centre
28.	ACTRN12616001138471	Cancer detection with a blood test.	20/10/2016	Early detection / screening	Individual
29.	ACTRN12620000315910	Post-operative high intensity interval training in patients undergoing major foregut cancer surgery: A randomised controlled trial	4/02/2020	Rehabilitation	St Vincent's Hospital
30.	ACTRN12618000232235	Ibudilast for the prevention of nerve symptoms caused by oxalipatin chemotherapy, in patients with metastatic gastrointestinal cancer	8/05/2018	Supportive care	Concord Cancer Centre
31.	ACTRN12617000152325	Enhancing quality of life for people with upper gastrointestinal cancer through early and intensive nutrition care delivered by telephone or mobile electronic messages.	7/04/2017	Supportive care	Individual
32.	ACTRN12620000409976	Prehabilitation for Gastrointestinal Cancer Surgery	13/01/2020	Prehabilitation	Concord Repatriation General Hospital
33.	ACTRN12619000194167	The effect of wearing an activity tracker on the length of hospital stay for gastrointestinal cancer patients: A randomised controlled trial (the Fit-4-Home Trial)	25/03/2019	Rehabilitation	Sydney Local Health District
34.	ACTRN12621000251820	Pharmacogenomics guided dosing of anticancer therapies for patients with cancer	17/03/2021	Pharmacogenetics	Peter MacCallum Cancer Centre
35.	ACTRN12619000152123	Limited Routine Total Parenteral Nutrition versus oral diet progression post Whipple procedure to assess affect on patient functionality	29/04/2019	Rehabilitation	Sydney Local Health District
36.	ACTRN12618001691235	Breath-Hold in Abdominal & Lung Cancer Radiotherapy - Tumour Reproducibility, Tumour Stability & Patient Experience	9/05/2019	Chemotherapy and/or radiotherapy	Austin Health

37.	ACTRN12620001290987	PROMISE: Patient Reported Outcome Measures in cancer care: a hybrid effectiveness-Implementation trial to optimise Symptom control and health service Experience	25/01/2021	Supportive care	QIMR Berghofer Medical Research Institute
38.	ACTRN12620000458932p	Australian MRI-Linac Patient Imaging Trial	13/04/2022	Specialist diagnostic work-up	South Western Sydney Local Health District
39.	ACTRN12619001094167	Can Pre-operative High Intensity Interval Exercise Improve Surgical Outcomes After Major Abdominal Surgery?	1/02/2021	Prehabilitation	Hunter New England Local Health District
40.	CTRI/2013/12/004236	Curative Value of Nitric Oxide Releasing Research Material on Various Cancers	5/08/1999	Emerging therapies	Sinha Institute of Medical Science & Technology
<b><i>Industry-driven clinical trials, focused exclusively in pancreatic cancer</i></b>					
41.	NCT02117479	Study of Ruxolitinib in Pancreatic Cancer Patients (Janus 1)	19/03/2014	Treatment (for recurrent, residual or metastatic disease)	Incyte
42.	NCT01231347	QUILT-2.014: Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas (GAMMA)	7/04/2011	Treatment (for recurrent, residual or metastatic disease)	NantWorks LLC
43.	NCT02993731	A Study of Napabucasin plus Nab-paclitaxel with Gemcitabine in Adult Patients with Metastatic Pancreatic Adenocarcinoma (CanStem111P)	1/12/2016	Treatment (for recurrent, residual or metastatic disease)	Sumitomo Dainippon Pharma Oncology, Inc
44.	NCT03941093	Evaluation of Efficacy and Safety of Neoadjuvant Treatment With Pamrevlumab in Combination With Chemotherapy (Gemcitabine and Nab-paclitaxel) in Locally Advanced Pancreatic Cancer	10/05/2019	Targeted therapy	FibroGen Inc
45.	NCT01964430	Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients with Resected Pancreatic Cancer (the Apact Study) (Apact)	28/03/2014	Chemotherapy and/or radiotherapy	Celgene Corp
46.	NCT00844649	Phase III Study of ABI-007 (Albumin-bound Paclitaxel) Plus Gemcitabine Versus	8/05/2009	Treatment (for recurrent, residual or metastatic disease)	Celgene Corp

		Gemcitabine in Metastatic Adenocarcinoma of the Pancreas			
47.	NCT02184195	Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-based Chemotherapy (POLO)	16/12/2014	Treatment (for recurrent, residual or metastatic disease)	AstraZeneca Plc
48.	NCT02923921	Study of Pegilodecakin (LY3500518) With FOLFOX Compared to FOLFOX Alone Second-line Tx in Participants With Metastatic Pancreatic Cancer (Sequoia)	1/03/2017	Treatment (for recurrent, residual or metastatic disease)	Eli Lilly and Co
49.	NCT01494506	Study of MM-398 with or Without 5-FU/LV, versus 5-FU/LV in Patients with Metastatic Pancreatic Cancer (NAPOLI-1)	11/01/2012	Treatment (for recurrent, residual or metastatic disease)	Merrimack Pharmaceuticals Inc
50.	NCT02715804	A Study of Pegylated Recombinant Human Hyaluronidase in Combination with Nab-Paclitaxel plus Gemcitabine Compared with Placebo plus Nab-Paclitaxel and Gemcitabine in Participants with Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma	14/03/2016	Treatment (for recurrent, residual or metastatic disease)	Halozyme Therapeutics Inc
51.	NCT01746979	Clinical Trial Testing TH-302 in Combination with Gemcitabine in Previously Untreated Subjects with Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma (MAESTRO)	1/01/2012	Treatment (for recurrent, residual or metastatic disease)	Threshold Pharmaceuticals
52.	NCT04083235	A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+gemcitabine Treatment (NAPOLI 3)	19/02/2020	Treatment (for recurrent, residual or metastatic disease)	Ipsen SA
53.	NCT02101021	Gemcitabine and Nab-paclitaxel Combined with Momelotinib in Participants with Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma	2/06/2014	Treatment (for recurrent, residual or metastatic disease)	Sierra Oncology Inc

54.	NCT01395017	Dasatinib Added to Gemcitabine for Subjects with Locally-advanced Pancreatic Cancer (LAPC)	1/06/2011	Targeted therapy	Otsuka Holdings Co Ltd
55.	NCT02981342	A Study of Abemaciclib (LY2835219) Alone or in Combination with Other Agents in Participants with Previously Treated Pancreatic Ductal Adenocarcinoma	12/01/2017	Treatment (for recurrent, residual or metastatic disease)	Eli Lilly and Company
56.	NCT03003078	A Pilot Study of OncoSil Given to Patients with Pancreatic Cancer Treated with FOLFIRINOX or Gemcitabine+Abraxane (PanCO)	27/03/2017	Chemotherapy and/or radiotherapy	OncoSil Medical Ltd
57.	NCT02289898	Study of Gemcitabine, Abraxane plus Placebo Versus Gemcitabine, Abraxane plus one or two Truncated Courses of Demcizumab in Subjects with First-line Metastatic Pancreatic Ductal Adenocarcinoma (YOSEMITE)	31/12/2014	Treatment (for recurrent, residual or metastatic disease)	OncoMed Pharmaceuticals Inc (Inactive)
58.	NCT00652366	A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients with Metastatic Pancreatic Cancer	1/05/2008	Treatment (for recurrent, residual or metastatic disease)	F. Hoffmann-La Roche Ltd
59.	NCT01124786	A Study Comparing CO-1.01 with Gemcitabine as First Line Therapy in Patients with Metastatic Pancreatic Adenocarcinoma (LEAP)	4/08/2010	Treatment (for recurrent, residual or metastatic disease)	Clovis Oncology Inc
60.	NCT03816163	A Study to Assess the Antitumor Activity and Safety of IMAB362 in Combination with Nab-paclitaxel and Gemcitabine (Nab-P + GEM) as First Line Treatment in Subjects with Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma	15/03/2019	Treatment (for recurrent, residual or metastatic disease)	Astellas Pharma Global Development, Inc.
61.	ACTRN12606000015549	A Phase I Clinical Trial to Assess the Efficacy of Treatment with SIR-Spheres Microspheres in Patients with Liver Metastases from Primary Cancer of the Pancreas	1/10/2006	Treatment (for recurrent, residual or metastatic disease)	Sirtex Medical Ltd
62.	NCT04390763	Study of Efficacy and Safety of NIS793 (with and without Spartalizumab) in Combination with SOC Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)	16/10/2020	Treatment (for recurrent, residual or metastatic disease)	Novartis AG



63.	NCT02551991	Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients with Previously Untreated, Metastatic Pancreatic Adenocarcinoma	27/10/2015	Chemotherapy and/or radiotherapy	Ipsen SA
64.	NCT03517176	CEND-1 in Combination with Nabpaclitaxel and Gemcitabine in Metastatic Pancreatic Cancer	31/07/2018	Treatment (for recurrent, residual or metastatic disease)	Cend Therapeutics Inc
65.	NCT03611556	MEDI9447 (Oleclumab) Pancreatic Chemotherapy Combination Study	21/06/2018	Treatment (for recurrent, residual or metastatic disease)	AstraZeneca Plc
66.	NCT03412799	Study of SBP-101 Combined with Nab-paclitaxel and Gemcitabine in Pancreatic Cancer	4/06/2018	Treatment (for recurrent, residual or metastatic disease)	Panbela Therapeutics Inc
67.	NCT01189929	A Study of Gemcitabine and Demcizumab (OMP-21M18) with or Without Abraxane as 1st-line Treatment in Subjects with Locally Advanced or Metastatic Pancreatic Cancer	1/08/2010	Treatment (for recurrent, residual or metastatic disease)	OncoMed Pharmaceuticals Inc (Inactive)
68.	ACTRN12615000606583	Study of SBP-101 safety and tolerability in patients with previously treated pancreatic cancer	4/01/2016	Treatment (for recurrent, residual or metastatic disease)	Panbela Therapeutics Inc
<b><i>Industry-driven other cancer (including pancreatic cancer) clinical trials</i></b>					
69.	NCT03229200	Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib	22/05/2017	Targeted therapy	Pharmacyclics LLC
70.	NCT03906331	Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation	1/05/2020	Treatment (for recurrent, residual or metastatic disease)	Loxo Oncology Inc
71.	NCT03207867	Study of Efficacy and Safety of NIR178 and PDR001 Combination in Patients with Selected Solid Tumors and Non-hodgkin Lymphoma	28/08/2017	Treatment (for recurrent, residual or metastatic disease)	Novartis AG
72.	NCT04482309	A Phase II Study of T-DXd in Patients With Selected HER2 Expressing Tumors (DPT02)	18/08/2020	Targeted therapy	AstraZeneca Plc
73.	NCT02576431	A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors (NAVIGATE)	30/09/2015	Treatment (for recurrent, residual or metastatic disease)	Bayer AG

74.	NCT01953926	Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations (SUMMIT)	30/09/2013	Targeted therapy	Puma Biotechnology Inc
75.	NCT02568267	Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients with Solid Tumors Harboring NTRK1/2/3 (TRK A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) (STARTRK-2)	19/11/2015	Targeted therapy	F. Hoffmann-La Roche Ltd
76.	NCT03797326	Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants with Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)	12/02/2019	Targeted therapy	Merck & Co Inc
77.	NCT01078662	Open Label Study to Assess Efficacy and Safety of Olaparib in Confirmed Genetic BRCA1 or BRCA2 Mutation Pats	21/02/2010	Targeted therapy	AstraZeneca Plc
78.	NCT02608268	Phase I-Ib/II Study of MBG453 as Single Agent and in Combination with PDR001 in Patients With Advanced Malignancies	23/11/2015	Treatment (for recurrent, residual or metastatic disease)	Novartis AG
79.	NCT02658890	An Investigational Immuno-therapy Study of BMS-986205 given in Combination with Nivolumab and in Combination with Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have Spread	18/02/2016	Targeted therapy and immunotherapy	Bristol-Myers Squibb Co
80.	ACTRN1261800003279	A Phase I/II, Open-Label, Multi-Arm Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of AGEN1884 in Combination With AGEN2034 in Subjects With Metastatic or Locally Advanced Solid Tumors, and Expansion Into Select Solid Tumors	18/12/2017	Immunotherapy	Agenus Inc
81.	NCT02754141	An Investigational Immuno-therapy Study of Experimental Medication Bms-986179 given Alone and in Combination with Nivolumab	20/06/2016	Immunotherapy	Bristol-Myers Squibb Co

82.	NCT03184870	A Study of BMS-813160 in Combination with Chemotherapy or Nivolumab in Patients with Advanced Solid Tumors	4/08/2017	Treatment (for recurrent, residual or metastatic disease)	Bristol-Myers Squibb Co
83.	NCT03150810	Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination with Temozolomide (TMZ) in Participants with Locally Advanced or Metastatic Solid Tumors	12/07/2017	Treatment (for recurrent, residual or metastatic disease)	BeiGene Ltd
84.	NCT02703571	Study of Safety and Efficacy of Ribociclib and Trametinib in Patients with Metastatic or Advanced Solid Tumors	29/06/2016	Treatment (for recurrent, residual or metastatic disease)	Novartis AG
85.	NCT02799095	A Study of the Effects of ALKS 4230 on Subjects with Solid Tumors	25/05/2016	Targeted therapy	Alkermes Plc
86.	NCT01449058	A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients with Selected Advanced Solid Tumors	1/03/2012	Targeted therapy	Array BioPharma Inc
87.	NCT03637491	A Study of Avelumab, Binimetinib and Talazoparib in Patients with Locally Advanced or Metastatic RAS-mutant Solid Tumors	15/08/2018	Targeted therapy	Pfizer
88.	EudraCT-2019-001318-40	A Phase I/II Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of SN38-SPL9111 (Dep-SN38), a SN38 Dendrimer Conjugate, in Patients with Advanced Solid Tumours	1/08/2019	Chemotherapy and/or radiotherapy	Starpharma Holdings Ltd
89.	NCT04481009	A Study to Evaluate YH003 in Combination with Toripalimab (Anti-PD-1 mAb) in Subjects with Advanced Solid Tumors	1/07/2020	Treatment (for recurrent, residual or metastatic disease)	Eucure (Beijing) Biopharma Co Ltd
90.	NCT03905148	Study of the Safety and Pharmacokinetics of BGB-283 (Lifirfenib) and PD-0325901 (Mirdametinib) in Participants With Advanced or Refractory Solid Tumors	1/05/2019	Targeted therapy	BeiGene Ltd
91.	NCT02713529	Safety and Efficacy Study of AMG 820 and Pembrolizumab Combination in Select Advanced Solid Tumor Cancer	14/04/2016	Immunotherapy	Merck & Co Inc

92.	EudraCT-2017-003424-76	A Phase I/II Study in Which, CTX-SPL9111, the Trial Medication Will Be Administered to Evaluate the Safety, Tolerability, Pharmacokinetics (Distribution of CTX-SPL9111 in the Body) and Efficacy in Patients with Advanced Solid Tumours	30/01/2018	Chemotherapy and/or radiotherapy	Starpharma Holdings Ltd
93.	NCT03382340	IMX-110 in Patients with Advanced Solid Tumors	15/02/2018	Chemotherapy and/or radiotherapy	Immix BioPharma Inc
94.	NCT03098550	A Study to Test the Safety and Effectiveness of Nivolumab Combined With Daratumumab in Patients With Pancreatic, Non-Small Cell Lung or Triple Negative Breast Cancers, That Have Advanced or Have Spread	7/06/2017	Immunotherapy	Bristol-Myers Squibb Co
95.	NCT01562899	A Study of MEK162 and AMG 479 in Patients with Selected Solid Tumors	27/08/2012	Targeted therapy	Pfizer Inc
96.	NCT04205227	ENB003 Plus Pembrolizumab Phase Ib/IIa in Solid Tumors	18/01/2020	Targeted therapy and immunotherapy	ENB Therapeutics LLC
97.	NCT04644068	Study of AZD5305 as Monotherapy and in Combination with Anti-cancer Agents in Patients with Advanced Solid Malignancies (PETRA)	12/11/2020	Targeted therapy	AstraZeneca Plc
98.	ACTRN12619000385145	A Study of Engineic Dream Vectors (EDV's) Packaged with the Chemotherapy, E-EDV-D682 Given Simultaneously as Non-targeted EDVs Carrying an Immune Enhancer Called EDV-GC, in Participants with Advanced Pancreatic and Other Cancers Whose Disease Has Progressed After One or Two Treatment Regimes, or Where Other Standard Therapies Are Not Appropriate	4/03/2019	Targeted therapy	EnGeneIC Ltd
99.	NCT02926768	Phase I/II Study of CK-101 in NSCLC Patients and Other Advanced Solid Tumors	1/09/2016	Treatment (for recurrent, residual or metastatic disease)	Checkpoint Therapeutics Inc
100.	NCT02341625	A Study of BMS-986148 in Patients with Select Advanced Solid Tumors	17/06/2015	Immunotherapy	Bristol-Myers Squibb Co

101.	NCT03157128	Phase I/II Study of LOXO-292 in Patients with Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001) ((LIBRETTO-001))	9/05/2017	Treatment (for recurrent, residual or metastatic disease)	Loxo Oncology Inc
102.	NCT02829723	A Study of BLZ945 Single Agent or BLZ945 in Combination with PDR001 in Advanced Solid Tumors	21/10/2016	Targeted therapy and immunotherapy	Novartis AG
103.	NCT01307267	A Study of PF-05082566 as a Single Agent and in Combination with Rituximab	21/06/2011	Immunotherapy	Pfizer Inc
104.	NCT03811652	A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors	20/12/2018	Immunotherapy	AstraZeneca Plc
105.	ACTRN12617001573347	Clinical Study Investigating the Safety PG545 in Combination with Nivolumab in Patients with Advanced Solid Tumours and in Patients with Metastatic Pancreatic Cancer	24/10/2017	Treatment (for recurrent, residual or metastatic disease)	Scientia Clinical Research Ltd
106.	NCT01292655	Study to Evaluate the Safety and Tolerability of IV Doses of BMS-906024 in Subjects with Advanced or Metastatic Solid Tumors	3/03/2011	Treatment (for recurrent, residual or metastatic disease)	Bristol-Myers Squibb Co
107.	NCT03549000	A Phase I/Ib Study of NZV930 Alone and in Combination with PDR001 and /or NIR178 in Patients with Advanced Malignancies	18/07/2018	Targeted therapy	Novartis AG
108.	NCT04430842	Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S	20/07/2020	Treatment (for recurrent, residual or metastatic disease)	Quadriga BioSciences Inc
109.	NCT03102320	Phase Ib Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors (ARCS-Multi)	26/05/2017	Treatment (for recurrent, residual or metastatic disease)	Bayer AG
110.	ACTRN12616000787482	Safety and Tolerability of MIL-38/Gallium67 (MILGa) in Patients with Advanced Prostate, Bladder and Pancreatic Cancer	18/08/2016	Specialist diagnostic work-up	Minomic International Ltd
111.	NCT02407990	Study of the Safety, Pharmacokinetics and Antitumor Activities of BGB-A317 in Participants With Advanced Tumors	2/06/2015	Immunotherapy	BeiGene Ltd
112.	NCT04148937	A Study of the CD73 Inhibitor LY3475070 Alone or in Combination with Pembrolizumab in Participants with Advanced Cancer	16/01/2020	Targeted therapy and immunotherapy	Eli Lilly and Co

113.	NCT02475213	Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab or MGA012 in Refractory Cancer	1/07/2015	Immunotherapy	MacroGenics Inc
114.	NCT03948763	A Study of mRNA-5671/V941 as Monotherapy and in Combination with Pembrolizumab (V941-001)	26/06/2019	Immunotherapy	Merck & Co Inc
115.	CP-MGD009-01; NCT02628535; CDR789768	Safety Study of MGD009 in B7-H3-expressing Tumors	1/09/2015	Immunotherapy	MacroGenics Inc
116.	NCT01966445	Dose Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2849330 in Subjects with Advanced Her3-positive Solid Tumors	26/11/2013	Immunotherapy	GlaxoSmithKline Plc
117.	NCT03529526	An Open-Label, Multi-center, Dose-Escalation Phase I Study to Evaluate Safety, Tolerability, Pharmacokinetics and Immunogenicity of KN046 in Subjects With Advanced Solid Tumors	28/05/2018	Immunotherapy	Alphamab Co. Ltd
118.	NCT02014116	A Study of LY3009120 in Participants with Advanced Cancer or Cancer That Has Spread to Other Parts of Their Body	26/11/2013	Treatment (for recurrent, residual or metastatic disease)	Eli Lilly and Co
119.	NCT02517398	MSB0011359C (M7824) in Metastatic or Locally Advanced Solid Tumors		Immunotherapy	Merck KGaA
120.	NCT02660034	The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination with BGB-290 in Participants with Advanced Solid Tumors	2/02/2016	Targeted therapy and immunotherapy	BeiGene Ltd
121.	NCT02824042	Thorough ECG (Electrocardiogram) and Drug Interaction Study with Anetumab Ravtansine and Itraconazole	7/09/2016	Treatment (for recurrent, residual or metastatic disease)	Bayer AG
122.	NCT01576666	Phase Ib, Dose Escalation Study of Oral LDE225 in Combination with BKM120 in Patients with Advanced Solid Tumors	4/07/2012	Targeted therapy	Novartis AG
123.	NCT02857270	A Study of LY3214996 Administered Alone or in Combination with Other Agents in Participants with Advanced/Metastatic Cancer	29/09/2016	Treatment (for recurrent, residual or metastatic disease)	Eli Lilly and Co

124.	NCT03454451	CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers	25/04/2018	Targeted therapy and immunotherapy	Corvus Pharmaceuticals Inc
125.	NCT03666988	First Time in Humans (FTIH) Study of GSK3368715 in Participants with Solid Tumors and Diffuse Large B-cell Lymphoma (DLBCL)	22/10/2018	Targeted therapy	GlaxoSmithKline Plc
126.	ACTRN12614000171617	A Phase I Study of Dendrimer-docetaxel (DEP(TM) Docetaxel) in Patients with Advanced Cancer	12/03/2014	Chemotherapy and/or radiotherapy	Starpharma Holdings Ltd
127.	NCT02715531	A Study of the Safety and Efficacy of Atezolizumab Administered in Combination with Bevacizumab and/or Other Treatments in Participants with Solid Tumors	6/04/2016	Immunotherapy	F. Hoffmann-La Roche Ltd
128.	NCT03821935	Study to Determine the Safety, Tolerability, Pharmacokinetics and RP2D of ABBV-151 as a Single Agent and in Combination with ABBV-181 in Participants with Locally Advanced or Metastatic Solid Tumors	21/02/2019	Immunotherapy	AbbVie Inc
129.	NCT03900442	Phase 1 Study of PTX-100 in Patients With Advanced Malignancies	1/09/2019	Targeted therapy	Prescient Therapeutics Ltd
130.	NCT01774019	Preoperative Biliary Drainage in Resectable Pancreatic or Periampullary Cancer	20/02/2013	Surgery	Boston Scientific Corporation
131.	NCT03099824	A Phase I Study of the Safety and Pharmacokinetics of GC4711 (Oral Capsule) Compared to GC4419 (IV Infusion) and GC4711 (IV Infusion) in Healthy Volunteers	16/10/2018	Emerging therapies	Galera Therapeutics Inc
132.	NCT03096756	A Study of the Safety, Tolerability and Pharmacokinetics of Orally-administered GC4702 in Healthy Volunteers	26/07/2016	Emerging therapies	Galera Therapeutics Inc
133.	NCT03194139	A Study Designed to Compare the Safety and Pharmacokinetics of Intravenously Administered Superoxide Dismutase Mimetic GC4711 and GC4419 in Healthy Volunteers	25/09/2017	Emerging therapies	Galera Therapeutics Inc
134.	NCT04333134	A Trial of SHR3162 in Healthy Caucasian Volunteers	17/04/2020	Targeted therapy	Atridia Pty Ltd

135.	ACTRN12620000894998p	A Phase I, Randomised, Double Blind, Placebo-controlled Study of the Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of Amp945 Administered Orally to Healthy Adult Volunteers	8/10/2020	Targeted therapy	Amplia Therapeutics Ltd
136.	NCT04575311	A Study to Investigate the Pharmacokinetic Profile of Oral AB680 in Healthy Volunteers	20/10/2020	Targeted therapy	Arcus Biosciences Inc

\*OCP: *Optimal Care Pathway*



Table 2: Intervention focus of clinical trials in pancreatic cancer according to stages of the cancer trajectory in the Optimal Care Pathway (OCP)

	OCP Steps	Investigator-initiated			Industry-sponsored		
		Pancreatic cancer (exclusively) (n=25)	Other cancer (including pancreatic cancer) (n=15)	All trials (n=40)	Pancreatic cancer (exclusively) (n=28)	Other cancer (including pancreatic cancer) (n=68)	All trials (n=96)
<i>Step 1: Prevention and early detection</i>							
1.1	Prevention	0	0	0	0	0	0
1.2	Risk factors	0	0	0	0	0	0
1.3	Early detection/screening	0	1	1	0	0	0
<i>Step 2: Presentation, initial investigations and referral</i>							
2.1	Signs and symptoms	0	0	0	0	0	0
2.2	Assessments by the primary care practitioner	0	0	0	0	0	0
2.3	Initial referral	0	0	0	0	0	0
<i>Step 3: Diagnosis, staging and treatment planning</i>							
3.1	Specialist diagnostic work-up	4	1	5	0	1	1
3.1.2	Medical genetic testing (family risk)	0	0	0	0	0	0
3.1.3	Pharmacogenetics	0	1	1	0	0	0
3.2	Staging	2	0	2	0	0	0
3.3	Performance status	0	0	0	0	0	0
3.4	Treatment planning	2	0	2	0	0	0
3.5.1	Prehabilitation	1	2	3	0	0	0
3.5.2	Fertility preservation and contraception	0	0	0	0	0	0
<i>Step 4: Treatment (for non-metastatic disease)</i>							
4.1	Treatment intent	0	0	0	0	0	0
4.2.1	Surgery	1	0	1	0	1	1
4.2.2	Systemic chemotherapy and/or radiotherapy	8	1	9	3	4	7
4.2.3(i)	Targeted therapies	0	0	0	2	20	22
4.2.3(ii)	Immunotherapy	1	0	1	0	16	16
4.2.3(i) and (ii)	Targeted therapies and immunotherapy	0	0	0	0	6	6
4.2.4	Emerging therapies	0	1	1	0	3	3
4.3	Palliative care	0	0	0	0	0	0
4.4	Psycho-oncology	0	0	0	0	0	0
<i>Step 5: Care after initial treatment and recovery</i>							
5.1	Transitioning from active treatment	0	0	0	0	0	0
5.2	Follow-up care	0	0	0	0	0	0

5.2.1	Preventing secondary recurrence	0	0	0	0	0	0
<i>Step 6: Managing recurrent, residual or metastatic disease</i>							
6.1	Signs and symptoms of metastatic disease	0	0	0	0	0	0
6.2	Managing metastatic disease	0	0	0	0	0	0
6.3	Multidisciplinary team	0	0	0	0	0	0
6.4	Treatment (for recurrent, residual or metastatic disease)	4	0	4	23	17	40
6.5	Advance care planning	0	0	0	0	0	0
6.6	Palliative care	0	0	0	0	0	0
<i>Step 7: End-of-life care</i>							
7	End-of-life care	0	0	0	0	0	0
7.1	Multidisciplinary palliative care	0	0	0	0	0	0
Across OCP	Rehabilitation (steps 4, 5 & 6)	0	3	3	0	0	0
	Communication with primary care practitioner (steps 3, 4, 5 & 7)	0	0	0	0	0	0
	Supportive care	2	5	7	0	0	0
	Communication with patient, carer, family	0	0	0	0	0	0